About this FactMed analysis covering adverse side effect reports of ALBUMINAR-25 patients who developed URTICARIA.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 1 individuals taking ALBUMINAR-25 reported URTICARIA to the FDA. A total of 49 ALBUMINAR-25 drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between ALBUMINAR-25 and URTICARIA. In doing so, we compare ALBUMINAR-25 with other drugs that cause URTICARIA, to help you evaluate whether or not ALBUMINAR-25 causes URTICARIA. Likewise, this page shows the most highly-reported side effects of ALBUMINAR-25, so you can see if URTICARIA ranks among ALBUMINAR-25's most well-known side effects.
Summary Statistics
Reports of ALBUMINAR-25 causing URTICARIA: 1
Reports of any side effect of ALBUMINAR-25 : 49
Percentage of ALBUMINAR-25 patients where URTICARIA is a reported side effect: 2.0408%

FDA reports of any drug causing URTICARIA : 36582
Average percentage for all medicated patients where URTICARIA is reported as a complication: 0.2293%

Physician opinion on ALBUMINAR-25 as adverse event culprit:

Overall opinion for all reports of this drug:
Most frequent diagnoses/indications for prescribing ALBUMINAR-25:
PRODUCT USED FOR UNKNOWN INDICATION ( 9 patients )
HYPOALBUMINAEMIA ( 6 patients )
CARDIAC FAILURE ( 2 patients )
SURGERY ( 2 patients )
DRUG USE FOR UNKNOWN INDICATION ( 2 patients )
HAEMODYNAMIC INSTABILITY ( 2 patients )
METASTASES TO LYMPH NODES ( 2 patients )
NEPHROTIC SYNDROME ( 2 patients )
RENAL FAILURE ACUTE ( 2 patients )
URINE OUTPUT DECREASED ( 2 patients )
HEPATIC CIRRHOSIS ( 2 patients )
HYPOTENSION ( 2 patients )
MYASTHENIA GRAVIS ( 1 patients )
PLASMAPHERESIS ( 1 patients )
LIVER DISORDER ( 1 patients )
PNEUMONIA ( 1 patients )
ASCITES ( 1 patients )
CENTRAL VENOUS PRESSURE DECREASED ( 1 patients )
GENERALISED OEDEMA ( 1 patients )
LYMPHANGIOMA ( 1 patients )
( 0 patients )
Drugs with high FDA adverse event association with URTICARIA:

REMICADE (1991 patients)
ASPIRIN (1911 patients)
HUMIRA (1642 patients)
FOSAMAX (1264 patients)
TYSABRI (1220 patients)
ENBREL (1216 patients)
MAGNEVIST (1073 patients)
PREDNISONE (939 patients)
BENADRYL (931 patients)
AVELOX (880 patients)
SYNTHROID (841 patients)
ULTRAVIST 300 (814 patients)
METHOTREXATE (806 patients)
LISINOPRIL (797 patients)
LIPITOR (770 patients)
NEXIUM (646 patients)
CHANTIX (640 patients)
ZYRTEC (604 patients)
NIASPAN (593 patients)
CELEBREX (583 patients)
ACETAMINOPHEN (570 patients)
SINGULAIR (560 patients)
OMEPRAZOLE (559 patients)
ALBUTEROL (556 patients)
ATENOLOL (545 patients)
AVONEX (542 patients)
HYDROCHLOROTHIAZIDE (540 patients)
LYRICA (530 patients)
VIOXX (528 patients)
FOLIC ACID (526 patients)
XOLAIR (503 patients)
IBUPROFEN (488 patients)
SIMVASTATIN (487 patients)
ADVAIR DISKUS 100/50 (472 patients)
LEVOTHYROXINE SODIUM (469 patients)
CRESTOR (463 patients)
XANAX (459 patients)
METFORMIN HCL (455 patients)
VITAMIN D (449 patients)
ZOLOFT (442 patients)
LEVAQUIN (441 patients)
ULTRAVIST 150 (434 patients)
PLAVIX (434 patients)
BYETTA (432 patients)
LAMICTAL (423 patients)
LASIX (419 patients)
CYMBALTA (419 patients)
ALEVE (382 patients)
PREDNISONE TAB (378 patients)
SPIRIVA (376 patients)
AMOXICILLIN (370 patients)
LEXAPRO (368 patients)
ULTRAVIST 370 (357 patients)
ALEVE (CAPLET) (355 patients)
PREDNISOLONE (355 patients)
WELLBUTRIN (352 patients)
ALLEGRA (349 patients)
PRILOSEC (348 patients)
NEURONTIN (343 patients)
ULTRAVIST (PHARMACY BULK) (341 patients)
NORVASC (339 patients)
CALCIUM (322 patients)
TOPROL-XL (320 patients)
PREVACID (319 patients)
ZOCOR (317 patients)
PREMARIN (312 patients)
GAMMAGARD LIQUID (310 patients)
LANTUS (309 patients)
AUGMENTIN '125' (309 patients)
DIOVAN (302 patients)
ZOMETA (302 patients)
FUROSEMIDE (299 patients)
AMBIEN (293 patients)
COPAXONE (293 patients)
HEPARIN SODIUM INJECTION (292 patients)
PAXIL (287 patients)
MIRENA (285 patients)
GABAPENTIN (281 patients)
ZANTAC (278 patients)
COUMADIN (275 patients)
FORTEO (270 patients)
PROTONIX (269 patients)
LORAZEPAM (263 patients)
FISH OIL (263 patients)
MULTI-VITAMIN (262 patients)
SEROQUEL (261 patients)
WELLBUTRIN XL (258 patients)
VICODIN (258 patients)
MULTI-VITAMINS (256 patients)
ATIVAN (245 patients)
SOLU-MEDROL (242 patients)
ALLOPURINOL (241 patients)
ALPRAZOLAM (231 patients)
PERCOCET (227 patients)
TYLENOL (CAPLET) (224 patients)
MORPHINE (222 patients)
EFFEXOR (219 patients)
RANITIDINE (218 patients)
ZETIA (216 patients)
TEGRETOL (215 patients)
ZITHROMAX (214 patients)
REVLIMID (213 patients)
AMLODIPINE (212 patients)
CIPROFLOXACIN (209 patients)
EXJADE (208 patients)
CLONAZEPAM (206 patients)
FLONASE (206 patients)
PROZAC (206 patients)
METFORMIN (205 patients)
METOPROLOL TARTRATE (204 patients)
OXYCONTIN (202 patients)
LEVOXYL (201 patients)
VOLTAREN (199 patients)
CLARITIN (197 patients)
ZOFRAN (196 patients)
POTASSIUM CHLORIDE (196 patients)
LANSOPRAZOLE (195 patients)
ASCORBIC ACID (195 patients)
TRAMADOL HCL (192 patients)
SYMBICORT (191 patients)
GLUCOPHAGE (190 patients)
BEXTRA (190 patients)
WARFARIN SODIUM (188 patients)
VITAMIN E (185 patients)
DEXAMETHASONE (183 patients)
TYLENOL (182 patients)
SIMCOR (181 patients)
AREDIA (180 patients)
HYDROXYZINE (180 patients)
MULTIHANCE (178 patients)
INSULIN (178 patients)
KLONOPIN (176 patients)
VENTOLIN (175 patients)
NO CONCURRENT MEDICATION (175 patients)
FLUOROURACIL (175 patients)
DECADRON (174 patients)
ATARAX (174 patients)
ACTONEL (173 patients)
JANUVIA (170 patients)
LORATADINE (169 patients)
REBIF (169 patients)
OXYCODONE HCL (168 patients)
ACCUTANE (167 patients)
TRAZODONE HCL (165 patients)
DIGOXIN (165 patients)
ADVIL (164 patients)
CIMZIA (163 patients)
EFFEXOR XR (163 patients)
NAPROXEN (162 patients)
GLEEVEC (162 patients)
TOPAMAX (160 patients)
COZAAR (160 patients)
CELEXA (159 patients)
VITAMIN B-12 (159 patients)
METOPROLOL (157 patients)
CLONIDINE (157 patients)
DURAGESIC-100 (156 patients)
BACTRIM (156 patients)
FENTANYL (154 patients)
ALENDRONATE SODIUM (153 patients)
DEFINITY (153 patients)
BENICAR (149 patients)
HUMALOG (149 patients)
FLOMAX (149 patients)
CALCIUM CARBONATE (146 patients)
ACETYLSALICYLIC ACID SRT (146 patients)
ZYBAN (145 patients)
VALTREX (145 patients)
ERBITUX (144 patients)
VICTOZA (144 patients)
TRICOR (142 patients)
RAMIPRIL (141 patients)
NASONEX (141 patients)
DIAZEPAM (141 patients)
BONIVA (140 patients)
ALTACE (140 patients)
PRADAXA (139 patients)
NEULASTA (139 patients)
VALIUM (139 patients)
VANCOMYCIN (138 patients)
ROCEPHIN (138 patients)
LOVENOX (138 patients)
COREG (137 patients)
LORTAB (137 patients)
GLIPIZIDE (136 patients)
GADAVIST (136 patients)
LAMISIL (136 patients)
CARBOPLATIN (136 patients)
PEGASYS (135 patients)
FAMOTIDINE (134 patients)
MOBIC (134 patients)
AZITHROMYCIN (134 patients)
CYCLOPHOSPHAMIDE (134 patients)
HYDROCORTISONE (132 patients)
PRAVASTATIN (131 patients)
PARACETAMOL (131 patients)
BETASERON (131 patients)
PLAQUENIL (130 patients)
AVANDIA (130 patients)
RIBAVIRIN (130 patients)
FLOVENT (129 patients)
ALLI (127 patients)
FLUOXETINE (126 patients)
ENALAPRIL MALEATE (125 patients)
CETIRIZINE HCL (123 patients)
ACYCLOVIR (123 patients)
FOSAMAX PLUS D (122 patients)
MEDROL (122 patients)
OPTIRAY 350 (122 patients)
DIPHENHYDRAMINE HCL (121 patients)
Most common side effects for patients taking ALBUMINAR-25:
BLOOD PRESSURE DECREASED (11 patients)
INFUSION RELATED REACTION (7 patients)
HEPATITIS C POSITIVE (4 patients)
OXYGEN SATURATION DECREASED (4 patients)
HEPATIC FAILURE (3 patients)
HEPATITIS C ANTIBODY POSITIVE (3 patients)
TACHYCARDIA (3 patients)
HEPATITIS C VIRUS TEST POSITIVE (3 patients)
ANTINUCLEAR ANTIBODY POSITIVE (3 patients)
PYREXIA (3 patients)
HYPERSENSITIVITY (3 patients)
CHILLS (3 patients)
BLOOD CULTURE POSITIVE (2 patients)
PLATELET COUNT DECREASED (2 patients)
LOSS OF CONSCIOUSNESS (2 patients)
PRODUCT QUALITY ISSUE (2 patients)
KLEBSIELLA INFECTION (2 patients)
BACTERIAL INFECTION (2 patients)
BODY TEMPERATURE INCREASED (2 patients)
HYPOXIA (2 patients)
HYPOTENSION (2 patients)
PRURITUS (2 patients)
PULMONARY EMBOLISM (2 patients)
RASH (2 patients)
HEPATITIS C RNA POSITIVE (2 patients)
CROHN'S DISEASE (2 patients)
RESTLESSNESS (2 patients)
TRANSMISSION OF AN INFECTIOUS AGENT VIA A MEDICINAL PRODUCT (2 patients)
HEPATITIS B VIRUS TEST POSITIVE (2 patients)
HEPATITIS B POSITIVE (2 patients)
DYSKINESIA (2 patients)
HEPATITIS (2 patients)
HEPATITIS C (2 patients)
HEADACHE (2 patients)
FOAMING AT MOUTH (2 patients)
FLUSHING (2 patients)
FATIGUE (1 patients)
HAEMOGLOBIN DECREASED (1 patients)
HAEMOLYSIS (1 patients)
EYE SWELLING (1 patients)
ENTEROCOLONIC FISTULA (1 patients)
HEPATIC FUNCTION ABNORMAL (1 patients)
DYSPNOEA (1 patients)
HEPATITIS B CORE ANTIGEN POSITIVE (1 patients)
DRUG HYPERSENSITIVITY (1 patients)
HEPATITIS B SURFACE ANTIGEN POSITIVE (1 patients)
DIARRHOEA (1 patients)
ABDOMINAL DISCOMFORT (1 patients)
CYANOSIS (1 patients)
CULTURE URINE POSITIVE (1 patients)
CORONARY ARTERY INSUFFICIENCY (1 patients)
COOMBS DIRECT TEST POSITIVE (1 patients)
COMPLICATIONS OF TRANSPLANTED LIVER (1 patients)
CATHETER SITE HAEMORRHAGE (1 patients)
CARDIO-RESPIRATORY ARREST (1 patients)
BLOOD PRESSURE SYSTOLIC DECREASED (1 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (1 patients)
BLOOD PRESSURE FLUCTUATION (1 patients)
LABORATORY TEST ABNORMAL (1 patients)
LARGE INTESTINE PERFORATION (1 patients)
LIP SWELLING (1 patients)
LIVER TRANSPLANT (1 patients)
BLOOD GLUCOSE INCREASED (1 patients)
NEUTROPHIL COUNT DECREASED (1 patients)
NOSOCOMIAL INFECTION (1 patients)
ORTHOPNOEA (1 patients)
BLOOD FIBRINOGEN DECREASED (1 patients)
PALLOR (1 patients)
BLOOD CREATININE INCREASED (1 patients)
PNEUMONIA KLEBSIELLA (1 patients)
POST PROCEDURAL COMPLICATION (1 patients)
PRODUCT OUTER PACKAGING ISSUE (1 patients)
PRODUCT PACKAGING QUANTITY ISSUE (1 patients)
BLOOD BILIRUBIN INCREASED (1 patients)
PROTHROMBIN TIME PROLONGED (1 patients)
BACK PAIN (1 patients)
ASTHENIA (1 patients)
PULMONARY OEDEMA (1 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (1 patients)
ANAPHYLACTIC SHOCK (1 patients)
RECTAL HAEMORRHAGE (1 patients)
RENAL DISORDER (1 patients)
ANAPHYLACTIC REACTION (1 patients)
RETROPERITONEAL ABSCESS (1 patients)
SEROLOGY POSITIVE (1 patients)
SWELLING FACE (1 patients)
ALANINE AMINOTRANSFERASE INCREASED (1 patients)
ADVERSE EVENT (1 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (1 patients)
URINARY TRACT INFECTION FUNGAL (1 patients)
URINE OUTPUT DECREASED (1 patients)
URTICARIA (1 patients)
VENA CAVA THROMBOSIS (1 patients)
WHITE BLOOD CELL COUNT DECREASED (1 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.


Recent FactMed Activity for ALBUMINAR-25


Issue Description / Topic Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about URTICARIA and ALBUMINAR-25, post it here. You may receive a response from a fellow patient - or a leading expert in the field.
Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking ALBUMINAR-25, post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.
Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in ALBUMINAR-25. This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.
We are currently accepting registration for ALBUMINAR-25 experts. If you are a healthcare provider experienced in prescribing ALBUMINAR-25, please register here.
giCould not connect: